Resources

Selected
  • COVID-19
Type of publications
Regions
Diseases
Methodological quality (AMSTAR 2)

1589 results found

2024 ∙ Chue, W. X. Lienardi, L. A. Tan, T. Q. W. Kadir, I. A. Lam, J. C. M.

Immune thrombocytopenia exacerbation post COVID-19 vaccination: a systematic review and meta-analysis

  • All age groups
  • COVID-19
  • Safety
Methodological quality (AMSTAR 2):
Low
2024 ∙ Bytyci, J. Ying, Y. Lee, L. Y. W.

Immunocompromised individuals are at increased risk of COVID-19 breakthrough infection, hospitalization, and death in the post-vaccination era: A systematic review

  • All age groups
  • COVID-19
  • Efficacy/effectiveness
Methodological quality (AMSTAR 2):
Critically low
2024 ∙ Tian, Z. Chen, Y. Yao, Y. Chen, L. Zhu, X. Shen, Z. Yang, S. Jin, H.

Immunogenicity and risk factors for poor humoral immune response to SARS-CoV-2 vaccine in patients with autoimmune hepatitis: a systematic review and meta-analysis

  • All age groups
  • COVID-19
  • Efficacy/effectiveness
Methodological quality (AMSTAR 2):
Critically low
2024 ∙ Ma, B. M. Tam, A. R. Chan, K. W. Hung, I. F. N. Tang, S. C. W. Chan, T. M. Yap, D. Y.

Immunogenicity and Safety of the Three-Dose COVID-19 Vaccine Regimen in Patients Receiving Renal Replacement Therapy: A Systematic Review and Meta-Analysis

  • All age groups
  • COVID-19
  • Efficacy/effectiveness
  • Safety
  • Administration
Methodological quality (AMSTAR 2):
Low
2024 ∙ Ouyang, L. Lei, G. Gong, Y.

Immunogenicity of COVID-19 vaccines in patients with cirrhosis: A meta-analysis

  • All age groups
  • COVID-19
  • Efficacy/effectiveness
Methodological quality (AMSTAR 2):
Critically low
2024 ∙ Kavikondala, S. Haeussler, K. Wang, X. Spellman, A. Bausch-Jurken, M. T. Sharma, P. Amiri, M. Krivelyova, A. Vats, S. Nassim, M. Kumar, N. Van de Velde, N.

Immunogenicity of mRNA-1273 and BNT162b2 in Immunocompromised Patients: Systematic Review and Meta-analysis Using GRADE

  • Adults
  • Older adults
  • COVID-19
  • Efficacy/effectiveness
  • Administration
Methodological quality (AMSTAR 2):
Critically low
2024 ∙ Chenchula, S. Chandra, M. B. Adusumilli, M. B. Ghanta, S. N. Bommasani, A. Kuttiappan, A. Padmavathi, R. Amerneni, K. C. Chikatipalli, R. Ghanta, M. K. Reddy, S. S. Mythili Bai, K. Prakash, S. Jogender, G. Chavan, M. Balakrishnan, S.

Immunogenicity, clinical efficacy and safety of additional second COVID-19 booster vaccines against Omicron and its subvariants: A systematic review

  • All age groups
  • COVID-19
  • Efficacy/effectiveness
  • Administration
  • Safety
Methodological quality (AMSTAR 2):
Critically low
2024 ∙ Chirasuthat, S. Ratanapokasatit, Y. Thadanipon, K. Chanprapaph, K.

Immunogenicity, Effectiveness, and Safety of COVID-19 Vaccines among Patients with Immune-Mediated Dermatological Diseases: A Systematic Review and Meta-analysis

  • All age groups
  • COVID-19
  • Efficacy/effectiveness
  • Safety
Methodological quality (AMSTAR 2):
Low
2024 ∙ Sharifi Aliabadi, L. Azari, M. Taherian, M. R. Barkhordar, M. Abbas, S. A. M. Azari, M. Ahmadvand, M. Salehi, Z. Rouzbahani, S. Vaezi, M.

Immunologic responses to the third and fourth doses of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccines in cell therapy recipients: a systematic review and meta-analysis

  • Adults
  • Older adults
  • COVID-19
  • Efficacy/effectiveness
Methodological quality (AMSTAR 2):
Low
2024 ∙ Muharam, R. Ika Putri, Y. Fitriayu Andyra, A. Ezekia, K. Elya Charilda, F. Bagastoro, A. Abigail Faradina, A. Pratama, G. Kemal Harzif, A.

Impact of COVID-19 Vaccination on In Vitro Fertilization Outcomes: A Systematic Review

  • All age groups
  • COVID-19
  • Safety
Methodological quality (AMSTAR 2):
Critically low
Loading...